Table 1.
Literature review of acute kidney injury after HIPEC
| Author | Year | N | AKI (%) | Classification/cut-off | HIPEC regimens |
|---|---|---|---|---|---|
| Glehen et al.16 | 2003 | 216 | 1.3 | > 3 × ULN (NCI CTC) | CPL (1 mg/kg, max. 80 mg), MMC (0.7 mg/kg, max. 60 mg), CPL (0.7 mg/kg) + (MMC 0.5 mg/kg) |
| Verwaal et al.17 | 2004 | 102 | 4.9 | > 3 × ULN (NCI CTC) | MMC (25–40 mg/m2) |
| Kusamura et al.18 | 2007 | 247 | 5.7 | > 3 × ULN (NCI CTC) | CPL (25 mg/m2/L) + MMC (3.3 mg/m2/L), CPL (43 mg/L) + DOX (15.25 mg/L) |
| Canda et al.19 | 2013 | 30 | 26.1 | > 3 × ULN (NCI CTC) | CPL (75 mg/m2), MMC (10 mg/m2), CPL (75 mg/m2) + MMC (10 mg/m2) |
| Haslinger et al.43 | 2013 | 112 | 0.9 | n/a | MMC (30 mg + 10 mg at 60 min) |
| Hakeam et al.20 | 2014 | 53 | 3.7 | RIFLE | CPL (50 mg/m2) + DOX (15 mg/m2) |
| Arjona-Sanchez et al.21 | 2016 | 141 | 30.5 | RIFLE | MMC (15 mg/m2), TAX (60 mg/m2) |
| Bouhadjari et al.22 | 2016 | 21 | 33 | CreaCl < 30 ml/min | CPL (75 mg/m2) + MMC (20 mg/m2) |
| Sin et al.23 | 2017 | 47 | 40.4 | > 3 × ULN (NCI CTC) | CPL (90 mg/kg) |
| Naffouje et al.24 | 2018 | 58 | 20.7 | KDIGO | MMC (40 mg), CPL (45 mg/L) ± DOX (15 mg/L), MEL (50 mg/m2) |
| Ye et al.25 | 2018 | 99 | 11.1 | RIFLE | 5-FU (700–800 mg/m2) ± CPL (60 mg/m2) |
| Cata et al.26 | 2018 | 475 | 21.3 | AKIN | CPL (n/a), OXA (n/a), MMC (n/a) |
| Angeles et al.27 | 2019 | 66 | 48 | RIFLE | CPL (50–100 mg/m2) |
| Present study | 2020 | 157 | 31.8 | KDIGO | Multiple regimens (see Table 2) |
HIPEC hyperthermic intraperitoneal chemotherapy, ULN upper limit normal, NCI CTC National Cancer Institute Common Terminology Criteria, CreaCl creatinine clearance, RIFLE risk, injury, failure, loss, and end-stage kidney disease, AKIN Acute Kidney Injury Network, KDIGO Kidney Disease Improving Global Outcome, CPL cisplatin, MMC mitomycin C, DOX doxorubicin, TAX taxol, MEL melphalan, 5-FU 5-fluorouracil, OXA oxaliplatin, n/a not available